Asset Details
Do you wish to reserve the book?
Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer
Do you wish to request the book?
Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer
2022
Overview
Celastrol is a promising antitumor drug candidate, but the poor water solubility and cytotoxicity limit its clinical application. Herein, we synthesized a Celastrol (Cel)-chitosan oligosaccharide (CSO) conjugate (Cel-CSO) for drug delivery. Celastrol was conjugated to a CSO backbone via amide bond formation, which was verified by infrared spectrum (IR) analyses. The Cel-CSO contained ∼10 wt% of Celastrol showed excellent aqueous solubility (18.6 mg/mL) in comparation with the parent Celastrol. Cel-CSO significantly inhibited tumor growth, induced apoptosis, and effectively suppressed tumor metastasis in human pancreatic cancer cells (BxPC-3). While the cytotoxicity of Cel-CSO in hepatic cells (HL7702) was lower than that of the free Celastrol. Cel-CSO enhanced the anticancer efficacy, promoted the circulation time of Celastrol, and reduced the subacute toxicity, which indicated that CSO can be a promising Celastrol delivery system for pancreatic cancer therapy.
Publisher
Taylor & Francis,Taylor & Francis Ltd,Taylor & Francis Group
Subject
/ Animals
/ Antineoplastic Agents - administration & dosage
/ Antineoplastic Agents - pharmacology
/ Cell Survival - drug effects
/ Humans
/ Mice
/ Oligosaccharides - chemistry
/ Pancreatic Neoplasms - pathology
/ Pentacyclic Triterpenes - administration & dosage
/ Pentacyclic Triterpenes - pharmacology
/ Polymers
/ Toxicity
